Thermo Fisher (TMO) Details $5B Buyback, $8.9B Clario Deal
Snack-Sized Version:
Thermo Fisher announced a $5 billion share buyback and a major $8.875 billion acquisition of Clario Holdings. The new share repurchase program has no expiration date. In addition, the company just reported strong Q3 2025 results. It beat analyst estimates for revenue and EPS. According to the company’s press announcements, the Clario deal should close by mid-2026.
| Deal: At a Glance | |
|---|---|
| Value / price | $8.875 billion |
| Consideration | Cash |
| Expected close | By mid-2026 |
| Rationale | Bolster clinical research market presence. |
Source: Joint press release; 8‑K; merger filing.
| Earnings: At a Glance | |
|---|---|
| Latest quarter | Q3 2025 |
| Revenue | $11.12B (beat $10.91B) |
| EPS | $5.79 adjusted (beat $5.50) |
| Cash returns | $5B share buyback authorized. |
Source: Company investor relations; SEC filings.
Related Company News
Read the Full Meal:
Thermo Fisher just announced two major capital moves. The company authorized a new $5 billion share repurchase program. It also revealed an $8.875 billion cash deal to acquire Clario Holdings. These announcements follow a strong Q3 2025 earnings report, where the company beat expectations. As a key supplier of lab equipment, these moves show Thermo Fisher is using its strong cash flow to expand its clinical research services. The Clario deal is the next major catalyst.
Buyback, Acquisition, and Earnings
- Capital allocation: The company will buy back $5B in stock. It is also spending $8.875B cash on Clario.
- Growth drivers: The Clario acquisition boosts clinical research services. Clario’s platform supported many FDA drug approvals.
- Strong performance: Q3 revenue hit $11.12 billion, beating forecasts. Adjusted EPS also surpassed analyst expectations.
- Stock update: TMO stock trades near its 52-week high. It returned 39.7% over the past six months.
Quick links
- Official source: press release hub
- IR hub: events & presentations · filings
- Our coverage: Thermo Fisher Citigroup Neutral · Thermo Fisher Scientific News Hub
Why this can matter for TMO holders
- Capital returns: The $5B buyback can provide support for the stock price.
- Strategic growth: The Clario deal expands TMO into the digital clinical trial market.
- Financial strength: Strong Q3 earnings demonstrate core business health. This supports both the buyback and the acquisition.
What to watch next
- Official filing: Monitor the company’s SEC filings for more details on the deal.
- Acquisition updates: Watch for regulatory approvals for the Clario deal. This is expected to close by mid-2026.
- Next event: Look for Q4 2025 results on the investor calendar.
Mini FAQ
What is the new Thermo Fisher buyback?
The board authorized a $5 billion share repurchase program with no set expiration date.
Who is Thermo Fisher acquiring?
Thermo Fisher is acquiring Clario Holdings for $8.875 billion in cash to boost its clinical research services.
How were TMO’s Q3 2025 earnings?
The company beat estimates, reporting $11.12B in revenue and $5.79 in adjusted EPS.
Industry News
-
Danaher (DHR) Stock Update: Q3 Beat & Analyst Ratings November 8, 2025 -
Thermo Fisher (TMO) Holds Neutral Rating at Citigroup October 27, 2025 -
Wells Fargo Lifts Danaher (DHR) Target to $230 October 24, 2025 -
Thermo Fisher Scientific Gears Up for Earnings Reveal October 16, 2025 -
Danaher Sells Shares Amid Market Changes October 15, 2025 -
Thermo Fisher Scientific Soars Beyond Expectations October 10, 2025
Sector News
-
Vertex Pharmaceuticals earnings beat faces doubt (VRTX) November 20, 2025 -
Eli Lilly (LLY) Beats Q3 Expectations & Partners with NVIDIA November 19, 2025 -
Pfizer (PFE) Pivots: Metsera Deal & BioNTech Exit Signal New Era November 18, 2025 -
UnitedHealth Group (UNH) Stock Rebounds on Strong Q3 November 18, 2025 -
Regeneron Clinical Data and Earnings Boost Stock (REGN) November 16, 2025 -
Stryker 2025 Investor Day Highlights Strategy (SYK) November 14, 2025
Author
